Free Trial

Silverback Therapeutics (NASDAQ:SBTX) Shares Up 0.4% - Time to Buy?

Silverback Therapeutics logo with Medical background

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Free Report) shot up 0.4% on Monday . The company traded as high as $14.91 and last traded at $14.53. 2,890,457 shares traded hands during trading, an increase of 755% from the average session volume of 337,931 shares. The stock had previously closed at $14.47.

Silverback Therapeutics Trading Down 9.2%

The stock has a market capitalization of $486.78 million, a P/E ratio of -5.58 and a beta of 0.60. The company has a 50-day moving average price of $16.82 and a 200 day moving average price of $14.36.

About Silverback Therapeutics

(Get Free Report)

Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.

Featured Stories

Should You Invest $1,000 in Silverback Therapeutics Right Now?

Before you consider Silverback Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Silverback Therapeutics wasn't on the list.

While Silverback Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.